Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex presented positive Phase 1 results for CDX-622, a novel bispecific antibody targeting soluble SCF and TSLP, at the EAACI Annual Meeting. The data showed rapid, dose-dependent, and durable reductions in serum tryptase, confirming mast cell depletion, with no dose-limiting toxicities or serious adverse events.
Key figures
- Drug Name
- CDX-622
- Phase Of Trial
- Phase 1
- Mechanism
- bispecific antibody targeting soluble SCF and TSLP
- Study participants
- 80
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.